A Phase 2 interventional study of Placebo and AMG 531 (Romiplostim) in MDS, Myelodysplastic Syndromes and Thrombocytopenia, sponsored by Amgen. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-10-17.
Sponsored by Amgen · Phase 2, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Myelodysplastic Syndromes by Amgen — none open to participants now, none under way, none of them phase 3. Myelodysplastic Syndromes · Amgen.
Among the 11 studies in Myelodysplastic Syndromes by Amgen, this one is the 7th largest by enrollment, is one of 3 that started in 2006, is one of 5 in phase 2, and was the 3rd registered.
1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 324 are open to participants now.
Browse Myelodysplastic Syndromes studies →None of the 11 studies in Myelodysplastic Syndromes by Amgen is open now. The open studies under Myelodysplastic Syndromes, anywhere →
Of the 264 Myelodysplastic Syndromes studies recruiting now, 167 (63%) set no upper age limit and 70 (27%) stop at 75 or younger; 57 take children under 18; 17 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 3 started in 2006.
This study's enrollment of 69 is above the median of 40 across 1,611 interventional studies indexed under Myelodysplastic Syndromes.
Median enrollment 72 across the 11 interventional studies. Of the 11 that completed or were terminated, 10 (91%) have results posted.
This tab as a report to print or save as PDF → With an account.
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Myelodysplastic Syndromes by Amgen, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the effect of Romiplostim (AMG 531) on the incidence of clinically significant thrombocytopenic events (grade 3 or 4 and/or receipt of platelet transfusions) in subjects with low or intermediate risk Myelodysplastic Syndrome (MDS) receiving hypomethylating agents. It is hypothesized that Romiplostim administration, at the appropriate dose and schedule, will result in reduction in the incidence of clinically significant thrombocytopenic events in low or intermediate risk MDS subjects receiving hypomethylating agents.
Inclusion Criteria: - Diagnosis of MDS by bone marrow based on the World Health Organization (WHO) classification - Low, Intermediate-1 or Intermediate-2 risk category MDS using the IPSS (International Prognostic Scoring System) - Planned to receive either azacytidine 75 mg/m2 by subcutaneous administration each day for 7 days or decitabine 20 mg/m2 by intravenous administration each day for 5 days for at least 4 cycles Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
500 mcg AMG 531 weekly via subcutaneous injection + 75 mg/m2 azacitidine for 4 cycles
Biological: AMG 531 (Romiplostim) · Drug: Azacitidine
750 mcg AMG 531 weekly via subcutaneous injection + 20 mg/m2 decitabine for 4 cycles
Biological: AMG 531 (Romiplostim) · Drug: Decitabine
750 mcg AMG 531 weekly via subcutaneous injection + 75 mg/m2 azacitidine for 4 cycles
Biological: AMG 531 (Romiplostim) · Drug: Azacitidine
Placebo weekly via subcutaneous injection + 75 mg/m2 azacitidine for 4 cycles
Drug: Placebo · Drug: Azacitidine
Placebo weekly via subcutaneous injection + 20 mg/m2 decitabine for 4 cycles
Drug: Placebo · Drug: Decitabine
Subjects in the control group will receive a placebo subcutaneous injection on a weekly basis during the 4 cycle treatment period.
AMG 531 (Romiplostim) will be administered weekly by subcutaneous injection at a dose of 500 or 750 μg during Part A and 750 μg during Part B for the 4 cycle treatment period, depending on randomization.
hypomethylating agent
hypomethylating agent
Occurrence of a Clinically Significant Thrombocytopenic Event
Occurrence of a clinically significant thrombocytopenic event within the participant, defined as any platelet count obtained from day 15 of cycle 1 through the end of the interim follow-up visit that was less than 50 x 10\^9/L or receipt of platelet transfusions at any time through the interim follow-up visit.
Time frame: Treatment period (up to 20 weeks)
Hypomethylating Agent Dose Reduction and Delay Due to Thrombocytopenia
Occurrence of hypomethylating agent dose reduction and delay due to thrombocytopenia
Time frame: Treatment period (up to 20 weeks)
Achieving an Overall Response (Complete or Partial Response, CR or PR) at the End of the Treatment Period
CR = decrease in bone marrow blast (≤5%) and improvement in peripheral blood counts (Hgb ≥ 11 g/dL, platelets ≥ 100x10\^9/L, neutrophils ≥ 1x10\^9/L, peripheral blasts=0%). PR = improvement in peripheral blood counts plus a decrease in bone marrow blasts ≥50% but not ≤5, or decrease in International Prognostic Scoring System score.
Time frame: Treatment period (up to 20 weeks)
Platelet Transfusion
Occurrence of one or more platelet transfusions from study day 1 through the interim follow-up visit (16 weeks)
Time frame: Study day 1 through the interim follow-up visit (up to 20 weeks)
Participants in Part A were enrolled from 9 November 2006 through 31 August 2007; participants in Part B were enrolled from 26 March 2008 through 3 November 2008. Participants who enrolled in Part A were not eligible for enrollment in Part B.
| Milestone | Romiplostim (AMG 531) Placebo Plus Azacitidine | Romiplostim (AMG 531) 500 mcg Plus Azacitidine | Romiplostim (AMG 531) 750 mcg Plus Azacitidine | Romiplostim (AMG 531) Placebo Plus Decitabine | Romiplostim (AMG 531) 750 mcg Plus Decitabine |
|---|---|---|---|---|---|
| Started | 13 | 13 | 14 | 0 | 0 |
| Completed | 8 | 3 | 3 | 0 | 0 |
| Not completed | 5 | 10 | 11 | 0 | 0 |
| Withdrew: Adverse event | 3 | 3 | 2 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 1 | 1 | 0 | 0 |
| Withdrew: Disease progression | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Requirement for alternative therapy | 0 | 2 | 1 | 0 | 0 |
| Withdrew: Physician decision | 0 | 1 | 3 | 0 | 0 |
| Withdrew: Other | 1 | 2 | 3 | 0 | 0 |
| Withdrew: Protocol deviation | 0 | 0 | 1 | 0 | 0 |
| Milestone | Romiplostim (AMG 531) Placebo Plus Azacitidine | Romiplostim (AMG 531) 500 mcg Plus Azacitidine | Romiplostim (AMG 531) 750 mcg Plus Azacitidine | Romiplostim (AMG 531) Placebo Plus Decitabine | Romiplostim (AMG 531) 750 mcg Plus Decitabine |
|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 14 | 15 |
| Completed | 0 | 0 | 0 | 8 | 10 |
| Not completed | 0 | 0 | 0 | 6 | 5 |
| Withdrew: Noncompliance | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Adverse event | 0 | 0 | 0 | 2 | 1 |
| Withdrew: Disease progression | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 1 | 2 |
| Withdrew: Death | 0 | 0 | 0 | 2 | 1 |
Occurrence of a clinically significant thrombocytopenic event within the participant, defined as any platelet count obtained from day 15 of cycle 1 through the end of the interim follow-up visit that was less than 50 x 10\^9/L or receipt of platelet transfusions at any time through the interim follow-up visit.
| Participants | Romiplostim (AMG 531) Placebo Plus Azacitidine | Romiplostim (AMG 531) 500 mcg Plus Azacitidine | Romiplostim (AMG 531) 750 mcg Plus Azacitidine | Romiplostim (AMG 531) Placebo Plus Decitabine | Romiplostim (AMG 531) 750 mcg Plus Decitabine |
|---|---|---|---|---|---|
| Occurrence of a Clinically Significant Thrombocytopenic Event | 11 | 8 | 10 | 11 | 12 |
Occurrence of hypomethylating agent dose reduction and delay due to thrombocytopenia
| Participants | Romiplostim (AMG 531) Placebo Plus Azacitidine | Romiplostim (AMG 531) 500 mcg Plus Azacitidine | Romiplostim (AMG 531) 750 mcg Plus Azacitidine | Romiplostim (AMG 531) Placebo Plus Decitabine | Romiplostim (AMG 531) 750 mcg Plus Decitabine |
|---|---|---|---|---|---|
| Hypomethylating Agent Dose Reduction and Delay Due to Thrombocytopenia | 1 | 1 | 0 | 0 | 0 |
CR = decrease in bone marrow blast (≤5%) and improvement in peripheral blood counts (Hgb ≥ 11 g/dL, platelets ≥ 100x10\^9/L, neutrophils ≥ 1x10\^9/L, peripheral blasts=0%). PR = improvement in peripheral blood counts plus a decrease in bone marrow blasts ≥50% but not ≤5, or decrease in International Prognostic Scoring System score.
| Participants | Romiplostim (AMG 531) Placebo Plus Azacitidine | Romiplostim (AMG 531) 500 mcg Plus Azacitidine | Romiplostim (AMG 531) 750 mcg Plus Azacitidine | Romiplostim (AMG 531) Placebo Plus Decitabine | Romiplostim (AMG 531) 750 mcg Plus Decitabine |
|---|---|---|---|---|---|
| Achieving an Overall Response (Complete or Partial Response, CR or PR) at the End of the Treatment Period | 2 | 1 | 1 | 3 | 5 |
Occurrence of one or more platelet transfusions from study day 1 through the interim follow-up visit (16 weeks)
| Participants | Romiplostim (AMG 531) Placebo Plus Azacitidine | Romiplostim (AMG 531) 500 mcg Plus Azacitidine | Romiplostim (AMG 531) 750 mcg Plus Azacitidine | Romiplostim (AMG 531) Placebo Plus Decitabine | Romiplostim (AMG 531) 750 mcg Plus Decitabine |
|---|---|---|---|---|---|
| Platelet Transfusion | 9 | 6 | 5 | 8 | 7 |
Collected over Up to 20 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A Placebo | — | 9/13 (69.2%) | 11/13 (84.6%) |
| Part A Romiplostim 500 µg | — | 4/13 (30.8%) | 13/13 (100%) |
| Part A Romiplostim 750 µg | — | 10/14 (71.4%) | 14/14 (100%) |
| Part B Placebo | — | 8/14 (57.1%) | 14/14 (100%) |
| Part B Romiplostim 750 µg | — | 8/15 (53.3%) | 14/15 (93.3%) |
| Event | Part A Placebo | Part A Romiplostim 500 µg | Part A Romiplostim 750 µg | Part B Placebo | Part B Romiplostim 750 µg |
|---|---|---|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 3/13 | 1/13 | 1/14 | 3/14 | 4/15 |
| PyrexiaGeneral disorders | 2/13 | 0/13 | 1/14 | 0/14 | 2/15 |
| AnaemiaBlood and lymphatic system disorders | 1/13 | 0/13 | 2/14 | 0/14 | 0/15 |
| PneumoniaInfections and infestations | 1/13 | 0/13 | 2/14 | 2/14 | 2/15 |
| HypotensionVascular disorders | 0/13 | 0/13 | 2/14 | 0/14 | 0/15 |
| Urinary tract infectionInfections and infestations | 0/13 | 0/13 | 0/14 | 0/14 | 2/15 |
| PancytopeniaBlood and lymphatic system disorders | 1/13 | 0/13 | 0/14 | 0/14 | 0/15 |
| Atrial fibrillationCardiac disorders | 0/13 | 1/13 | 1/14 | 0/14 | 0/15 |
| Atrial flutterCardiac disorders | 0/13 | 1/13 | 0/14 | 0/14 | 0/15 |
| Sick sinus syndromeCardiac disorders | 0/13 | 1/13 | 1/14 | 0/14 | 0/15 |
| Event | Part A Placebo | Part A Romiplostim 500 µg | Part A Romiplostim 750 µg | Part B Placebo | Part B Romiplostim 750 µg |
|---|---|---|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 4/13 | 4/13 | 2/14 | 9/14 | 4/15 |
| ConstipationGastrointestinal disorders | 5/13 | 7/13 | 7/14 | 5/14 | 4/15 |
| NauseaGastrointestinal disorders | 6/13 | 4/13 | 6/14 | 6/14 | 5/15 |
| DiarrhoeaGastrointestinal disorders | 1/13 | 4/13 | 6/14 | 5/14 | 3/15 |
| FatigueGeneral disorders | 5/13 | 4/13 | 2/14 | 3/14 | 2/15 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 5/13 | 4/13 | 1/14 | 1/14 | 4/15 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 5/13 | 3/13 | 1/14 | 3/14 | 3/15 |
| Decreased appetiteMetabolism and nutrition disorders | 0/13 | 3/13 | 5/14 | 2/14 | 2/15 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 1/13 | 2/13 | 5/14 | 1/14 | 3/15 |
| ThrombocytopeniaBlood and lymphatic system disorders | 4/13 | 0/13 | 0/14 | 3/14 | 2/15 |
| Age, Continuous(Years) | Romiplostim (AMG 531) Placebo Plus Azacitidine | Romiplostim (AMG 531) 500 mcg Plus Azacitidine | Romiplostim (AMG 531) 750 mcg Plus Azacitidine | Romiplostim (AMG 531) Placebo Plus Decitabine | Romiplostim (AMG 531) 750 mcg Plus Decitabine | Total |
|---|---|---|---|---|---|---|
| Mean | 67.3 (58 to 86) | 71.9 (56 to 86) | 71.4 (61 to 81) | 70.5 (52 to 84) | 68.2 (55 to 81) | 69.8 (52 to 86) |
| Sex: Female, Male(Participants) | Romiplostim (AMG 531) Placebo Plus Azacitidine | Romiplostim (AMG 531) 500 mcg Plus Azacitidine | Romiplostim (AMG 531) 750 mcg Plus Azacitidine | Romiplostim (AMG 531) Placebo Plus Decitabine | Romiplostim (AMG 531) 750 mcg Plus Decitabine | Total |
|---|---|---|---|---|---|---|
| Female | 6 | 3 | 7 | 3 | 7 | 26 |
| Male | 7 | 10 | 7 | 11 | 8 | 43 |
| Race/Ethnicity, Customized(Participants) | Romiplostim (AMG 531) Placebo Plus Azacitidine | Romiplostim (AMG 531) 500 mcg Plus Azacitidine | Romiplostim (AMG 531) 750 mcg Plus Azacitidine | Romiplostim (AMG 531) Placebo Plus Decitabine | Romiplostim (AMG 531) 750 mcg Plus Decitabine | Total |
|---|---|---|---|---|---|---|
| White or Caucasian | 13 | 10 | 14 | 9 | 11 | 57 |
| Black or African American | 0 | 2 | 0 | 1 | 1 | 4 |
| Hispanic or Latino | 0 | 0 | 0 | 2 | 3 | 5 |
| Asian | 0 | 1 | 0 | 2 | 0 | 3 |
No study locations are listed for this record.
Ran from Oct 2006 to primary completion in Oct 2009, 36 months.
Results were first posted in Apr 2011, 1 year 5 months after primary completion.
Of 52 industry-sponsored phase 2 interventional studies under Myelodysplastic Syndromes, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 62. This study's 36 months is close to that.
Counting every sponsor, half of 279 studies reached it within 66 months; a quarter within 40 and three quarters within 104.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Romiplostim